MedTrace Logo

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

NCT03473613 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2018-03-29

No results posted yet for this study

Summary

Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

Conditions

  • Ovarian Hyperstimulation

Interventions

DRUG

Oral Cabergoline

Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days

DRUG

Calcium Gluconate

Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ashraf N Elmantwe, MD · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-01
Primary Completion
2017-04-15
Completion
2017-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03473613 on ClinicalTrials.gov